Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:18 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)
NCT03391765 · AbbVie · PHASE2 · terminated · last registry update 2021-02-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “This study was prematurely discontinued because the program for progressive supranuclear palsy was discontinued due to lack of efficacy.” | – | Registry record, AbbVie |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MAPT within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-02-03Results posted on the registry: AbbVie, Placebo + ABBV-8E12 (NCT02985879)
- 2021-02-03Also stopped (terminated): AbbVie, Placebo + ABBV-8E12 (NCT02985879)
- 2020-12-21Results posted on the registry: Biogen, BIIB092 + Placebo (NCT03068468)
- 2020-12-21Also stopped (terminated): Biogen, BIIB092 + Placebo (NCT03068468)
- 2020-05-18Also stopped (terminated): Biogen, BIIB092 (NCT02658916)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision